Leerink Swann Upgrades Medicines Company To Outperform
Analysts at Leerink Swann upgraded The Medicines Company (NASDAQ: MDCO) from Market Perform to Outperform.
The price target for Medicines Company has been raised from $24 to $31.
Medicines Company shares have declined 36.78% over the past 52 weeks, while the S&P 500 index has gained 9.63% in the same period.
Medicines Company's shares fell 1.52% to close at $24.70 yesterday.
Latest Ratings for MDCO
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2019 | SVB Leerink | Downgrades | Outperform | Market Perform |
| Nov 2019 | Chardan Capital | Downgrades | Buy | Neutral |
| Nov 2019 | Oppenheimer | Downgrades | Outperform | Perform |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Leerink SwannUpgrades Analyst Ratings
